Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Related Citations for PubMed (Select 23824676)

1.

CYP2B6*6 is associated with increased breast cancer risk.

Justenhoven C, Pentimalli D, Rabstein S, Harth V, Lotz A, Pesch B, Brüning T, Dörk T, Schürmann P, Bogdanova N, Park-Simon TW, Couch FJ, Olson JE, Fasching PA, Beckmann MW, Häberle L, Ekici A, Hall P, Czene K, Liu J, Li J, Baisch C, Hamann U, Ko YD, Brauch H.

Int J Cancer. 2014 Jan 15;134(2):426-30. doi: 10.1002/ijc.28356. Epub 2013 Jul 30.

2.

CYP2C19*17 is associated with decreased breast cancer risk.

Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Brüning T, Winter S, Ko YD, Brauch H.

Breast Cancer Res Treat. 2009 May;115(2):391-6. doi: 10.1007/s10549-008-0076-4. Epub 2008 Jun 3.

PMID:
18521743
3.

The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.

Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Brüning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H.

Breast Cancer Res Treat. 2008 Sep;111(1):171-7. Epub 2007 Oct 6.

PMID:
17922187
4.

Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.

Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C, Illig T, Pesch B, Brüning T, Dippon J, Ko YD, Brauch H.

Int J Cancer. 2009 May 1;124(9):2077-81. doi: 10.1002/ijc.24198.

PMID:
19142864
5.

The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, Southey MC, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):439-43.

6.

The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities.

Daraki A, Zachaki S, Koromila T, Diamantopoulou P, Pantelias GE, Sambani C, Aleporou V, Kollia P, Manola KN.

PLoS One. 2014 Feb 24;9(2):e88879. doi: 10.1371/journal.pone.0088879. eCollection 2014.

7.

ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population.

Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Brüning T, Brauch H.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2059-64.

8.

Functional polymorphisms in CD166/ALCAM gene associated with increased risk for breast cancer in a Chinese population.

Zhou P, Du LF, Lv GQ, Yu XM, Gu YL, Li JP, Zhang C.

Breast Cancer Res Treat. 2011 Jul;128(2):527-34. doi: 10.1007/s10549-011-1365-x. Epub 2011 Feb 4.

PMID:
21293922
9.

CYP1B1 C4326G polymorphism and susceptibility to cervical cancer in Chinese Han women.

Li Y, Tan SQ, Ma QH, Li L, Huang ZY, Wang Y, Li SW.

Tumour Biol. 2013 Dec;34(6):3561-7. doi: 10.1007/s13277-013-0935-4. Epub 2013 Jun 23.

PMID:
23794133
10.
11.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV.

Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23.

12.

CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.

Bloom AJ, Martinez M, Chen LS, Bierut LJ, Murphy SE, Goate A.

PLoS One. 2013 Nov 15;8(11):e79700. doi: 10.1371/journal.pone.0079700. eCollection 2013.

13.

Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk.

Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB, Neugut AI, Josephy PD, Ambrosone CB.

Cancer Res. 2004 Oct 15;64(20):7634-9.

14.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H.

J Clin Oncol. 2007 Nov 20;25(33):5187-93.

15.

CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.

Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P.

Ann Hematol. 2011 Mar;90(3):293-9. doi: 10.1007/s00277-010-1085-z. Epub 2010 Sep 28.

PMID:
20878158
16.

SULT1A1 Arg213His polymorphism, smoked meat, and breast cancer risk: a case-control study and meta-analysis.

Lee H, Wang Q, Yang F, Tao P, Li H, Huang Y, Li JY.

DNA Cell Biol. 2012 May;31(5):688-99. doi: 10.1089/dna.2011.1403. Epub 2011 Oct 19.

PMID:
22011087
17.

Catechol-O-methyltransferase and cytochrome P-450 1B1 polymorphisms and endometrial cancer risk: a meta-analysis.

Teng Y, He C, Zuo X, Li X.

Int J Gynecol Cancer. 2013 Mar;23(3):422-30. doi: 10.1097/IGC.0b013e3182849e0d.

PMID:
23370603
18.

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.

Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H.

HIV Med. 2007 Mar;8(2):86-91.

PMID:
17352764
19.

Estrogen receptor alpha gene polymorphisms and breast cancer risk: a case-control study with meta-analysis combined.

Lu H, Chen D, Hu LP, Zhou LL, Xu HY, Bai YH, Lin XY.

Asian Pac J Cancer Prev. 2014 Jan;14(11):6743-9.

20.

Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer.

Harlid S, Butt S, Ivarsson MI, Eyfjörd JE, Lenner P, Manjer J, Dillner J, Carlson J.

BMC Womens Health. 2012 Jun 22;12:17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk